JPMorgan lowered the firm’s price target on Moderna (MRNA) to $45 from $59 and keeps an Underweight rating on the shares. The firm updated ...

Moderna stock is undervalued with a $97 price target, strong COVID-19 revenue, promising pipeline, and long-term growth. Read ...

The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...

Trump’s picks, made late Friday, did little to dispel the notion that the nation’s federal health agencies are facing a major ...

Marty Makary, an outspoken critic of the nation’s food and drug regulator, stands to shake up the FDA’s standards in science ...

WASHINGTON — Johns Hopkins surgeon Marty Makary has criticized – sometimes with harsh language – the Food and Drug ...

Makary and Weldon, who have criticized the agencies they may soon run, were joined by Janette Nesheiwat, Trump’s pick to be ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

President-elect Donald Trump has nominated a critic of COVID-19 health measures to lead the Food and Drug Administration.

When the COVID pandemic began, there was lots of chatter about the possibility of being simultaneously infected with other ...

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the ...